Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy Study of Eculizumab in Paroxysmal Nocturnal Hemoglobinuria Patients

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Japanese individuals at least 12 years of age~* Diagnosis of PNH \> 6 months~* At least one transfusion in the past 2 years for anemia or anemia-related symptoms~* LDH level ≥ 1.5 x upper limit of normal within 12 weeks~* Presence of a glycosylphosphatidylinositol (GPI)-deficient red blood cell (RBC) clone (type III cells) by flow cytometry of ≥10%~* Negative serum pregnancy test for women of child-bearing potential~Exclusion Criteria:~* Platelet count \< 30,000/µL~* Absolute neutrophil count ≤ 500/µL~* Known or suspected hereditary complement deficiency~* History of hematopoietic stem cell transplant~* History of meningococcal disease

- Gender: ALL
- Minimum Age: 12 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Eculizumab (Type: EXPERIMENTAL): Eculizumab intravenous infusions every week x 4 doses, then 900 mg 1 week later for 1 dose, then 900 mg every 2 weeks for 4 doses

Based on this trial design, predict the completion outcome and termination type (if applicable).